Christopher R Kieliszak, DO
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 9
Offices
9 locations · Palm Harbor Dermatology PA · Lakeland Regional Health Systems Inc · Western New York Medical Practice PC · Rochester General Hospital
Hospitals listed: Rochester General Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kieliszak’s office to ask if they take your plan before you enroll.
State licence records
1 licence
- Florida OS19621Osteopathic Physician · since 2023 · expires 2028-03-31Matched by name, not licence number; check the name before relying on it.ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
4 placements
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Education
- New York Institute of Technology Main CA · DO2008–2012Medical school
Residency and fellowship
- Mittelman Plastic Surgery Center, PLASTIC SURGERY WITHIN THE HEAD AND NECKLOS ALTOS, CA · 2018–2019
- OhioHealth Doctors Hospital, OTOLARYNGOLOGYColumbus, OH · 2014–2018
- core doctors hospital, OTOLARYNGOLOGYcolumbus, OH · 2014–2018
- Adena Regional Medical Center, OSTEOPATHIC INTERNSHIP/RESIDENCYChillicothe, OH · 2012–2013
What else the board holds
Hospitals they may admit to
Where the clinician told their state board they may admit and treat patients.
- Out of State · FL
Also licensed in
States the clinician told their board they are also licensed in. Only the states we check are verified.
California
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Rochester General HospitalRochester, NYAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Rochester Regional Health System, which runs 6 hospitalsPatients rate it 2 of 5 · 60% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.75 (1.49 to 2.01), Jul 2022 – Jun 2024Worse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.59 (3.69 to 7.49) · 1,934 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative hemorrhage or hematoma rate: 4.42 (3.1 to 5.73) · 1,826 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 2.27 (1.72 to 2.82) · 5,687 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.544, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.477, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.522, Oct 2024 – Sep 2025
See every measure and the patient survey for Rochester General Hospital
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 2 worse of 8 measures. Readmissions: 0 better, 8 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.75 (1.49 to 2.01) | Worse | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.59 (3.69 to 7.49) · 1,934 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 4.42 (3.1 to 5.73) · 1,826 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 2.27 (1.72 to 2.82) · 5,687 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.544 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.477 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.522 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.54 (0.63 to 2.45) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 173.53 (128.98 to 218.07) · 110 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.6 · 70 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.6 · 142 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 346 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 240 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.8 · 634 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 7,150 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.35 (0.15 to 0.55) · 6,752 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.39 (0.19 to 0.58) · 7,066 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.46 (0.03 to 2.88) · 986 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.02 (6.1 to 15.95) · 952 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.01 (3.93 to 10.09) · 992 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.82 (0.4 to 3.24) · 419 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 264 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.674 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.728 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.49 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.7 · 678 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.8 · 1,625 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.1 · 188 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 44.4 · 417 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 84.2 · 233 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17 · 944 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.1 (2.7 to 6) · 145 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 8.9 (6.5 to 12) · 145 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 7.7 · 261 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 188 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.4 · 508 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.5 to 17) · 396 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.2) · 590 cases | No different | Jan 2024 – Dec 2024 |
What patients said (3,464 patients answered, 23% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 58% |
| Nurses "always" communicated well | 71% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 59% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 60% |
| Staff "always" explained possible side effects | 39% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$1,927
Medicare paid this office $1,927 for 24 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of skin lesions | 1-10 | None |
| Skin biopsy | 1-10 | None |
Who their Medicare patients are
24 Original Medicare patients in 2024. Average age 72 · Also on Medicaid 46% · Health risk score 1.40. Above the middle of the specialty; the typical otolaryngology clinician is at 1.19.
Conditions among them: High blood pressure 75%.
The office billed $7,361, Medicare allowed $3,151 and paid $1,927; for 38 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 24 | 38 | 72 | 1.40 | $7,361 | $1,927 |
| 2023 | 108 | 226 | 69 | 0.96 | $43,229 | $12,864 |
| 2022 | 110 | 335 | 71 | 1.07 | $50,829 | $18,168 |
| 2021 | 91 | 287 | 68 | 1.48 | $64,041 | $25,153 |
| 2020 | 114 | 308 | 66 | 1.47 | $48,432 | $20,457 |
| 2019 | 29 | 59 | 68 | 1.50 | $10,132 | $4,642 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Short return visit (20+ min) | 48 | $2,711 | $51 |
| Diagnostic exam of voice box using a flexible endoscope | 22 | $1,276 | $55 |
| New patient visit (30+ min) | 20 | $1,273 | $64 |
| New patient visit (45+ min) | 12 | $1,186 | $99 |
| Removal of impacted ear wax | 12 | $409 | $29 |
2022: 9 services
| Short return visit (20+ min) | 44 | $2,560 | $53 |
| Diagnostic exam of voice box using a flexible endoscope | 28 | $2,245 | $70 |
| Return visit (30+ min) | 24 | $2,228 | $83 |
| New patient visit (30+ min) | 32 | $1,913 | $60 |
| New patient visit (45+ min) | 12 | $1,147 | $96 |
| Diagnostic exam of nasal passages using an endoscope | 11 | $1,104 | $92 |
| Professional service for multiple injections of allergen | 21 | $696 | $8 |
| Comprehensive hearing and speech recognition test | 12 | $240 | $20 |
| Test to assess middle ear function | 12 | $85 | $7 |
2021: 9 services
| Short return visit (20+ min) | 43 | $3,917 | $68 |
| Diagnostic exam of voice box using a flexible endoscope | 20 | $2,408 | $89 |
| Diagnostic exam of nasal passages using an endoscope | 17 | $2,203 | $130 |
| New patient visit (30+ min) | 27 | $2,029 | $75 |
| New patient visit (45+ min) | 14 | $1,744 | $125 |
| Return visit (30+ min) | 14 | $1,662 | $87 |
| Comprehensive hearing and speech recognition test | 16 | $478 | $28 |
| Removal of impacted ear wax | 12 | $418 | $30 |
| Test for eardrum and muscle function | 17 | $296 | $16 |
2020: 6 services
| Short return visit (20+ min) | 68 | $4,735 | $55 |
| Diagnostic exam of nasal passages using an endoscope | 16 | $2,705 | $150 |
| New patient visit (30+ min) | 32 | $2,571 | $80 |
| Diagnostic exam of voice box using a flexible endoscope | 20 | $2,046 | $85 |
| Comprehensive hearing and speech recognition test | 19 | $664 | $30 |
| Test for eardrum and muscle function | 20 | $405 | $17 |
2019: 2 services
| Short return visit (20+ min) | 14 | $908 | $57 |
| New patient visit (30+ min) | 11 | $907 | $82 |
Medicaid work
$273 in 2023
Medicaid paid $273 for 31 billed services this clinician did in 2023, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Professional services for allergen immunotherapy not including provision of allergenic extracts; 2 or more injections | 31 | $273 |
| 2023 | 31 | 1 | 13 | $273 |
| 2022 | 111 | 1 | 21 | $987 |
| 2020 | 136 | 2 | 27 | $10,288 |
| 2019 | 20 | 1 | 19 | $1,189 |
See the largest Medicaid services in earlier years
2022
| Professional services for allergen immunotherapy not including provision of allergenic extracts; 2 or more injections | 111 | $987 |
2020
| Short return visit (20+ min) | 90 | $5,854 |
| New patient visit (30+ min) | 46 | $4,434 |
2019
| Short return visit (20+ min) | 20 | $1,189 |
Drugs they prescribed that Part D paid
$1,489
Pharmacies billed $1,489 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 12% of their Part D prescriptions (12 of 100) in 2024. Above the middle of the specialty; the typical otolaryngology clinician is at 4%.
96 generic and fewer than 11 brand-name prescriptions · $1,489 in drug cost · 25 antibiotic prescriptions to 20 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Cephalexin | 11 | $45 | $3 |
Year by year
| 2024 | 100 | 38 | 12% (12) | None | $1,489 |
| 2023 | 163 | 91 | None | 13% | $41,063 |
| 2022 | 256 | 125 | 6% (16) | 7% | $8,297 |
| 2021 | 287 | 118 | 6% (16) | 6% | $10,190 |
| 2020 | 328 | 120 | 5% (15) | 7% | $9,853 |
| 2019 | 109 | 64 | 12% (13) | 18% | $4,576 |
| 2018 | 54 | 26 | None | None | $1,230 |
| 2017 | 62 | 34 | 18% (11) | 0% | $1,084 |
| 2016 | 77 | 40 | 23% (18) | None | $898 |
| 2015 | 31 | 16 | None | None | $642 |
| 2014 | 22 | 12 | None | None | $580 |
| 2013 | 100 | 16 | None | None | $3,344 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Mometasone Furoate | 11 | $764 | $69 |
| Azelastine | 11 | $272 | $25 |
| Fluticasone Propionate | 13 | $213 | $16 |
| Amoxicillin | 12 | $36 | $3 |
2022: 7 drugs
| Ipratropium | 21 | $1,224 | $58 |
| Fluticasone Propionate | 43 | $750 | $17 |
| Azelastine | 17 | $645 | $38 |
| Levothyroxine | 14 | $253 | $18 |
| Hydrocodone-Acetaminophen | 16 | $179 | $11 |
| Famotidine | 12 | $101 | $8 |
| Mupirocin | 14 | $97 | $7 |
2021: 9 drugs
| Ciprofloxacin-Dexamethasone | 12 | $2,196 | $183 |
| Ipratropium | 31 | $1,711 | $55 |
| Fluticasone Propionate | 48 | $1,349 | $28 |
| Azelastine | 36 | $1,259 | $35 |
| Famotidine | 18 | $288 | $16 |
| Hydrocodone-Acetaminophen | 15 | $87 | $6 |
| Mupirocin | 11 | $76 | $7 |
| Montelukast | 15 | $64 | $4 |
| Clindamycin | 11 | $41 | $4 |
2020: 11 drugs
| Fluticasone Propionate | 64 | $1,059 | $17 |
| Ipratropium | 22 | $939 | $43 |
| Famotidine | 25 | $470 | $19 |
| Azelastine | 14 | $409 | $29 |
| Montelukast | 33 | $283 | $9 |
| Amoxicillin-Clavulanate Potass | 13 | $184 | $14 |
| Mupirocin | 12 | $77 | $6 |
| Hydrocodone-Acetaminophen | 15 | $63 | $4 |
| Clindamycin | 11 | $42 | $4 |
| Cephalexin | 13 | $36 | $3 |
| Prednisone | 11 | $30 | $3 |
2019: 3 drugs
| Ciprodex | 11 | $2,727 | $248 |
| Hydrocodone-Acetaminophen | 13 | $82 | $6 |
| Cephalexin | 13 | $69 | $5 |
2017: 1 drug
| Fluticasone Propionate | 12 | $147 | $12 |
2016: 2 drugs
| Ranitidine | 21 | $179 | $9 |
| Fluticasone Propionate | 13 | $150 | $12 |
2013: 3 drugs
| Risperidone | 18 | $164 | $9 |
| Propylthiouracil | 17 | $124 | $7 |
| Phenytoin Sodium Extended | 15 | $94 | $6 |
Money from drug and device companies
$59 in 2025
| 2025 | 2 | 3 | None | $59 |
| 2023 | 3 | 3 | None | $185 |
| 2022 | 5 | 10 | None | $334 |
| 2021 | 4 | 4 | None | $434 |
| 2020 | 5 | 7 | None | $490 |
| 2019 | 4 | 4 | None | $195 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| GlaxoSmithKline | Nucala | $40 | 2 payments
|
| Stryker | Scopis Ent | $20 | 1 payment
|
See all 3 published payments
| Stryker | Meals · 2025-04-10 | Scopis Ent | $20 |
| GlaxoSmithKline | Meals · 2025-03-13 | Nucala | $22 |
| GlaxoSmithKline | Meals · 2025-01-30 | Nucala | $18 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $185
| GlaxoSmithKline | Nucala | $112 | 1 payment
|
| Stryker | Scopis Ent | $47 | 1 payment
|
| Smith+Nephew | Tula | $27 | 1 payment
|
2022: $334
| GlaxoSmithKline | Nucala | $155 | 6 payments
|
| Genzyme | Dupixent | $96 | 1 payment
|
| Stryker | Scopis Ent | $38 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $24 | 1 payment
|
| ALK-Abello | Odactra | $21 | 1 payment
|
2021: $434
| Aerin Medical | Vivaer Stylus | $223 | 1 payment
|
| Stryker | Xpress Ent Dilation System | $169 | 1 payment
|
| Ambu | None | $24 | 1 payment
|
| Optinose US | Xhance | $18 | 1 payment
|
2020: $490
| Smith+Nephew | Procise Max | $275 | 3 payments
|
| Stryker | Entellus - Xpress Ent Dilation System | $160 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $25 | 1 payment
|
| ALK-Abello | Odactra | $20 | 1 payment
|
| Aerin Medical | Vivaer | $10 | 1 payment
|
2019: $195
| Vioptix | T. Ox Tissue Oximeter | $152 | 1 payment
|
| Stryker | Entellus - Xpress Ent Dilation System | $16 | 1 payment
|
| Merz North America | Xeomin | $15 | 1 payment
|
| OptiNose US | Xhance | $12 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 95.2 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1346508421
- Licence
- NY 300797Florida OS19621: Active
- Group
- Palm Harbor Dermatology PA · Lakeland Regional Health Systems Inc · Western New York Medical Practice PC · Rochester General Hospital
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207YS0123X (207YS0123X)
- Mailing address
- 700 S Harbour Island Blvd Unit 137, Tampa, FL, 33602
- NPI first listed
- 2012-04-26
- NPI last updated
- 2025-08-06
- NPI record certified
- 2025-08-06
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 395 West Ave Ste 301, Canandaigua, NY, 14424 · 4638 Genesee St, Geneseo, NY, 14454 · 810 Altos Oaks Dr, Los Altos, CA, 94024 · 1206 Driving Park Ave, Newark, NY, 14513 · 1425 S Howard Ave, Tampa, FL, 33606